BI 706039 / Boehringer Ingelheim - LARVOL DELTA

The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of Inflammatory Bowel Disease. (PubMed, Am J Physiol Gastrointest Liver Physiol) - "A relatively low oral dose of a potent and selective RIPK2 inhibitor can block the signaling interface between the intestinal microbiome and the intestinal immune system and significantly improve disease associated intestinal inflammation."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • RIPK2

[VIRTUAL] BI 706039 IS A POTENT AND SELECTIVE INHIBITOR OF RIPK2 AND IMPROVES INTESTINAL INFLAMMATION IN THE TRUC MOUSE MODEL OF INFLAMMATORY BOWEL DISEASE. (DDW 2021) - "These observations correlated with dose-responsively increasing systemic levels of the BI 706039 compound, splenic molecular target engagement of RIPK2 (100% at doses ≥ 2.5 mg/kg) and modulation of inflammatory genes in the colon. This demonstrates that a relatively low oral dose of a potent and specific RIPK2 inhibitor can block the signaling interface between the intestinal microbiome and the intestinal immune system and lead to significantly improved intestinal inflammation."

Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • RIPK2 • TNFA